AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pfizer's Trading Volume Drops 25.43% to $997 Million Ranking 77th Amid $6 Billion Cancer Drug Deal
Generated by AI AgentAinvest Market Brief
Wednesday, May 21, 2025 7:40 pm ET1min read
On May 21, 2025, Pfizer's trading volume reached $997 million, marking a 25.43% decrease from the previous day. This placed
at the 77th position in terms of trading volume for the day. Pfizer's stock price fell by 2.04%.Pfizer has entered into a significant agreement with 3SBio to develop and market a cancer drug outside of China. This deal, valued at up to $6 billion, grants Pfizer exclusive rights to develop and sell the drug in markets beyond China. The agreement includes an upfront payment of $1.25 billion to 3SBio, with additional milestone payments of up to $4.8 billion.
BMO Capital has maintained its buy rating on Pfizer's stock following the announcement of the $6 billion cancer drug deal. This strategic move is expected to bolster Pfizer's oncology portfolio and enhance its market position in the global cancer treatment landscape.
Ainvest Market Brief
Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.
Latest Articles
Morning Market Pulse: Trump Trade War Threats and Fed Uncertainty Weigh on Markets
Dec.23 2025
What to Trade Today: Gold and Copper Rally as Biotech and Metals Stocks Offer Volatile Short-Term Gaps
Dec.23 2025
U.S. Corporate Actions | Ticker Changes and Dividend Announcements Highlight Activity
Dec.23 2025
Morning Market Pulse: Trump Housing Overhaul & AI Surge Drive Pre-Market Moves
Dec.22 2025
Morning Market Pulse: Trump’s Federal Pay Raise & Japan’s Policy Shift Drive Pre-Market Moves
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet